241 related articles for article (PubMed ID: 33479485)
1. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema.
Cicinelli MV; Rosenblatt A; Grosso D; Zollet P; Capone L; Rabiolo A; Lattanzio R; Loewenstein A; Bandello F;
Eye (Lond); 2021 Dec; 35(12):3232-3242. PubMed ID: 33479485
[TBL] [Abstract][Full Text] [Related]
2. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results.
Elbarky AM
Eur J Ophthalmol; 2021 Nov; 31(6):3196-3202. PubMed ID: 33426902
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
[TBL] [Abstract][Full Text] [Related]
5. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months.
Roth DB; Eichenbaum D; Malik D; Radcliffe NM; Cutino A; Small KW;
Ophthalmol Retina; 2024 Jan; 8(1):49-54. PubMed ID: 37586482
[TBL] [Abstract][Full Text] [Related]
6. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E
Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
[TBL] [Abstract][Full Text] [Related]
8. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
[TBL] [Abstract][Full Text] [Related]
9. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
[TBL] [Abstract][Full Text] [Related]
10. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
[TBL] [Abstract][Full Text] [Related]
11. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema.
Merrill PT; Holekamp N; Roth D; Kasper J; Grigorian R;
Am J Ophthalmol; 2023 Apr; 248():16-23. PubMed ID: 36223849
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
Currie CJ; Holden SE; Berni E; Owens DR
Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143
[TBL] [Abstract][Full Text] [Related]
13. Changes in Ganglion Cell Layer Thickness after Treatment with the 0.2 µg/day Fluocinolone Acetonide Implant in Vitrectomized and Nonvitrectomized Eyes with Diabetic Macular Edema.
Pessoa B; Castro C; Ferreira A; Leite J; Heitor J; Menéres P; Figueira J; Meireles A; Beirão JM
Ophthalmic Res; 2022; 65(3):310-320. PubMed ID: 35086095
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with the response to fluocinolone acetonide 0.19 mg in diabetic macular oedema evaluated as the area-under-the-curve.
Cicinelli MV; Rabiolo A; Capone L; Di Biase C; Lattanzio R; Bandello F
Eye (Lond); 2023 Feb; 37(2):242-248. PubMed ID: 35094025
[TBL] [Abstract][Full Text] [Related]
15. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
[TBL] [Abstract][Full Text] [Related]
16. Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve.
Kessler LJ; Auffarth GU; Khoramnia R
J Ocul Pharmacol Ther; 2023 Sep; 39(7):449-455. PubMed ID: 37384926
[No Abstract] [Full Text] [Related]
17. BETTER BASELINE VISION LEADS TO BETTER OUTCOMES AFTER THE 0.19-mg FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN DIABETIC MACULAR EDEMA.
Gonzalez VH; Luo C; Almeida DRP; Cutino A; Coughlin B; Kasper J; Kiernan DF; ; ;
Retina; 2023 Aug; 43(8):1301-1307. PubMed ID: 37130434
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results.
Dobler E; Mohammed BR; Chavan R; Lip PL; Mitra A; Mushtaq B
Eye (Lond); 2023 Aug; 37(11):2310-2315. PubMed ID: 36513858
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Anatomical and Functional Outcomes of Intravitreal Dexamethasone Implant between Phakic and Pseudophakic Eyes with Diabetic Macular Edema.
Kaldırım H; Savur F; Kırgız A; Atalay K
Korean J Ophthalmol; 2020 Oct; 34(5):383-391. PubMed ID: 33099560
[TBL] [Abstract][Full Text] [Related]
20. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom.
Bailey C; Chakravarthy U; Lotery A; Menon G; Talks J;
Eye (Lond); 2017 Dec; 31(12):1707-1715. PubMed ID: 28737758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
